<DOC>
	<DOCNO>NCT01986088</DOCNO>
	<brief_summary>A previously publish , placebo-controlled , head-to-head comparator study find eletriptan superior efficacy oral sumatriptan 100 mg treat single acute migraine attack . The goal current study extend finding study examine efficacy eletriptan compare 50- 100-mg dos sumatriptan ; evaluate comparative efficacy eletriptan sumatriptan across additional important clinical outcome . In particular , early response ( 1 hour ) , sustain response ( without need additional treatment ) 24 hour , consistency response across multiple attack examine .</brief_summary>
	<brief_title>Eletriptan v Sumatriptan : A Double-blind , Placebo-controlled , Multiple Migraine Attack Study</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Sumatriptan</mesh_term>
	<mesh_term>Eletriptan</mesh_term>
	<criteria>Eligible patient men woman minimum age limit 18 year age ( Canada also age limit 65 year ) expect least one attack migraine without aura , define International Headache Society ( IHS ) criteria,15 every 6 week . Patients capable take study medication outpatient record effect . Pregnant breastfeed woman use adequate contraception exclude trial . Patients frequent nonmigrainous headache , atypical migraine previously respond therapy , migraine prolong aura , familial hemiplegic migraine , basilar migraine , migrainous infarction exclude trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>76 Years</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>